OPK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
OPK is not a good buy right now for an impatient trader. The setup is still technically bearish (downtrend with negative momentum) and there are no Intellectia buy signals to override that. While insider/hedge-fund buying and extremely call-skewed options positioning are supportive, price is still below key resistance (pivot 1.325) and near support (1.252). I would wait for either (1) a clean reclaim of 1.325 with improving momentum, or (2) a decisive bounce off 1.252 with confirmation—otherwise the path of least resistance remains lower into the next month.
Trend/momentum: Bearish. Moving averages are stacked negatively (SMA_200 > SMA_20 > SMA_5), confirming a sustained downtrend. MACD histogram is negative (-0.00417) and expanding lower, suggesting downside momentum is still building rather than stabilizing. RSI(6) at 33.77 is weak and near oversold-adjacent, which can allow a short bounce, but it is not a reversal signal by itself.
Key levels: Price ~1.27 is sitting just above S1 (1.252). If 1.252 breaks, next support is S2 (1.208). Overhead, pivot resistance is 1.325, then R1 1.398.
Near-term statistical bias: Pattern-based projection suggests downside skew (60% chance of ~-0.6% next day, ~-0.67% next week, ~-5.34% next month).
Intellectia Proprietary Trading Signals
Positioning/flows: Hedge funds are buying aggressively (reported +1498.79% QoQ buying amount) and insiders are also buying (+1295.35% MoM), which is a meaningful positive signal for sentiment and potential valuation support.
Profitability mix improvement: Gross margin improved sharply in 2025/Q3 (to ~20.02, +76.54% YoY), suggesting better unit economics or mix even while revenue is down.
Potential event catalyst ahead: Next earnings is scheduled for 2026-02-25 (after hours), which can become a catalyst if results/forward commentary improve versus expectations (EPS est. -0.07).
Technical downtrend: Bearish MA stack + weakening MACD indicates momentum still points down; overhead resistance at ~1.325 is close and likely to cap rallies unless reclaimed.
Growth deterioration (latest quarter): 2025/Q3 revenue (-12.65% YoY), net income (-13.09% YoY), and EPS (-25% YoY) all declined—fundamentals are not currently supporting a sustained rerating.
Analyst stance: JPMorgan initiated with Neutral and explicitly wants clinical validation before turning constructive; that limits near-term institutional enthusiasm.
No fresh news this week: Lack of near-term narrative catalysts increases the chance price action follows the prevailing bearish trend.
Latest reported quarter: 2025/Q3. Revenue fell to $151.669M (-12.65% YoY). Net income decreased to $21.631M (-13.09% YoY). EPS declined to $0.03 (-25% YoY). The notable bright spot is gross margin rising to ~20.02 (+76.54% YoY), indicating improved margin structure, but the top-line contraction and lower EPS keep the overall growth picture negative.
Recent trend: Limited coverage update provided; the key datapoint is JPMorgan initiation (2025-11-20) at Neutral with no price target, citing OPK as multi-faceted but requiring clinical validation before investor buy-in.
Wall Street pros: diversified healthcare exposure (diagnostics + pipeline), potential upside if clinical validation materializes. Wall Street cons: early-stage pipeline risk/uncertainty and lack of near-term validation, plus weakening YoY financial growth metrics.
Influential/politician trading: No recent congress trading data available in the last 90 days.
